Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 269

1.

D-578, an orally active triple monoamine reuptake inhibitor, displays antidepressant and anti-PTSD like effects in rats.

Dutta AK, Santra S, Harutyunyan A, Das B, Lisieski MJ, Xu L, Antonio T, Reith MEA, Perrine SA.

Eur J Pharmacol. 2019 Nov 5;862:172632. doi: 10.1016/j.ejphar.2019.172632. Epub 2019 Aug 29.

PMID:
31473161
2.

Molecular Mechanisms of Amphetamines.

Reith MEA, Gnegy ME.

Handb Exp Pharmacol. 2019 Jul 9. doi: 10.1007/164_2019_251. [Epub ahead of print]

PMID:
31286212
3.

Biased signaling agonist of dopamine D3 receptor induces receptor internalization independent of β-arrestin recruitment.

Xu W, Reith MEA, Liu-Chen LY, Kortagere S.

Pharmacol Res. 2019 May;143:48-57. doi: 10.1016/j.phrs.2019.03.003. Epub 2019 Mar 4.

PMID:
30844536
4.

Selective activation of Dopamine D3 receptors and norepinephrine transporter blockade enhances sustained attention.

Marshall CA, Brodnik ZD, Mortensen OV, Reith MEA, Shumsky JS, Waterhouse BD, España RA, Kortagere S.

Neuropharmacology. 2019 Apr;148:178-188. doi: 10.1016/j.neuropharm.2019.01.003. Epub 2019 Jan 8.

PMID:
30633928
5.

Design, Synthesis, and Pharmacological Characterization of Carbazole Based Dopamine Agonists as Potential Symptomatic and Neuroprotective Therapeutic Agents for Parkinson's Disease.

Elmabruk A, Das B, Yedlapudi D, Xu L, Antonio T, Reith MEA, Dutta AK.

ACS Chem Neurosci. 2019 Jan 16;10(1):396-411. doi: 10.1021/acschemneuro.8b00291. Epub 2018 Oct 24.

PMID:
30301349
6.

Tamoxifen Directly Interacts with the Dopamine Transporter.

Mikelman SR, Guptaroy B, Schmitt KC, Jones KT, Zhen J, Reith MEA, Gnegy ME.

J Pharmacol Exp Ther. 2018 Oct;367(1):119-128. doi: 10.1124/jpet.118.248179. Epub 2018 Aug 14.

PMID:
30108161
7.

Latch and trigger role for R445 in DAT transport explains molecular basis of DTDS.

Reith MEA, Jones KT, Zhen J, Topiol S.

Bioorg Med Chem Lett. 2018 Feb 1;28(3):470-475. doi: 10.1016/j.bmcl.2017.12.016. Epub 2017 Dec 8.

8.

Functional properties of dopamine transporter oligomers after copper linking.

Zhen J, Reith MEA.

J Neurochem. 2018 Jan;144(2):162-171. doi: 10.1111/jnc.14259. Epub 2017 Dec 21.

9.

Dopamine transporter phosphorylation site threonine 53 is stimulated by amphetamines and regulates dopamine transport, efflux, and cocaine analog binding.

Challasivakanaka S, Zhen J, Smith ME, Reith MEA, Foster JD, Vaughan RA.

J Biol Chem. 2017 Nov 17;292(46):19066-19075. doi: 10.1074/jbc.M117.787002. Epub 2017 Sep 22.

10.

A Novel Iron(II) Preferring Dopamine Agonist Chelator as Potential Symptomatic and Neuroprotective Therapeutic Agent for Parkinson's Disease.

Das B, Kandegedara A, Xu L, Antonio T, Stemmler T, Reith MEA, Dutta AK.

ACS Chem Neurosci. 2017 Apr 19;8(4):723-730. doi: 10.1021/acschemneuro.6b00356. Epub 2017 Jan 27.

PMID:
28106982
11.

Effects of diet and insulin on dopamine transporter activity and expression in rat caudate-putamen, nucleus accumbens, and midbrain.

Jones KT, Woods C, Zhen J, Antonio T, Carr KD, Reith ME.

J Neurochem. 2017 Mar;140(5):728-740. doi: 10.1111/jnc.13930. Epub 2017 Jan 31.

12.

Functional Characterization of a Novel Series of Biased Signaling Dopamine D3 Receptor Agonists.

Xu W, Wang X, Tocker AM, Huang P, Reith ME, Liu-Chen LY, Smith AB 3rd, Kortagere S.

ACS Chem Neurosci. 2017 Mar 15;8(3):486-500. doi: 10.1021/acschemneuro.6b00221. Epub 2016 Nov 23.

13.

Novel multifunctional dopamine D2/D3 receptors agonists with potential neuroprotection and anti-alpha synuclein protein aggregation properties.

Luo D, Sharma H, Yedlapudi D, Antonio T, Reith MEA, Dutta AK.

Bioorg Med Chem. 2016 Nov 1;24(21):5088-5102. doi: 10.1016/j.bmc.2016.08.021. Epub 2016 Aug 20.

PMID:
27591013
14.

Impact of disruption of secondary binding site S2 on dopamine transporter function.

Zhen J, Reith ME.

J Neurochem. 2016 Sep;138(5):694-9. doi: 10.1111/jnc.13704. Epub 2016 Jul 14. Review.

15.

Efficacy of Hybrid Tetrahydrobenzo[d]thiazole Based Aryl Piperazines D-264 and D-301 at D₂ and D₃ Receptors.

Zhen J, Antonio T, Jacob JC, Grandy DK, Reith MEA, Dutta AK, Selley DE.

Neurochem Res. 2016 Feb;41(1-2):328-339. doi: 10.1007/s11064-015-1808-6. Epub 2015 Dec 31.

17.

Insulin enhances striatal dopamine release by activating cholinergic interneurons and thereby signals reward.

Stouffer MA, Woods CA, Patel JC, Lee CR, Witkovsky P, Bao L, Machold RP, Jones KT, de Vaca SC, Reith ME, Carr KD, Rice ME.

Nat Commun. 2015 Oct 27;6:8543. doi: 10.1038/ncomms9543.

18.

Mutations in SLC12A5 in epilepsy of infancy with migrating focal seizures.

Stödberg T, McTague A, Ruiz AJ, Hirata H, Zhen J, Long P, Farabella I, Meyer E, Kawahara A, Vassallo G, Stivaros SM, Bjursell MK, Stranneheim H, Tigerschiöld S, Persson B, Bangash I, Das K, Hughes D, Lesko N, Lundeberg J, Scott RC, Poduri A, Scheffer IE, Smith H, Gissen P, Schorge S, Reith ME, Topf M, Kullmann DM, Harvey RJ, Wedell A, Kurian MA.

Nat Commun. 2015 Sep 3;6:8038. doi: 10.1038/ncomms9038.

19.

Use of radiolabeled antagonist assays for assessing agonism at D2 and D3 dopamine receptors: comparison with functional GTPγS assays.

Zhen J, Antonio T, Ali S, Neve KA, Dutta AK, Reith ME.

J Neurosci Methods. 2015 Jun 15;248:7-15. doi: 10.1016/j.jneumeth.2015.03.028. Epub 2015 Apr 1.

PMID:
25840364
20.

Dopamine transporter oligomerization: impact of combining protomers with differential cocaine analog binding affinities.

Zhen J, Antonio T, Cheng SY, Ali S, Jones KT, Reith ME.

J Neurochem. 2015 Apr;133(2):167-73. doi: 10.1111/jnc.13025. Epub 2015 Jan 26.

21.

Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter.

Reith ME, Blough BE, Hong WC, Jones KT, Schmitt KC, Baumann MH, Partilla JS, Rothman RB, Katz JL.

Drug Alcohol Depend. 2015 Feb 1;147:1-19. doi: 10.1016/j.drugalcdep.2014.12.005. Epub 2014 Dec 18. Review.

22.

Pharmacological and behavioral characterization of D-473, an orally active triple reuptake inhibitor targeting dopamine, serotonin and norepinephrine transporters.

Dutta AK, Santra S, Sharma H, Voshavar C, Xu L, Mabrouk O, Antonio T, Reith ME.

PLoS One. 2014 Nov 26;9(11):e113420. doi: 10.1371/journal.pone.0113420. eCollection 2014.

23.

Design, synthesis, and structure-activity relationship studies of a series of [4-(4-carboxamidobutyl)]-1-arylpiperazines: insights into structural features contributing to dopamine D3 versus D2 receptor subtype selectivity.

Ananthan S, Saini SK, Zhou G, Hobrath JV, Padmalayam I, Zhai L, Bostwick JR, Antonio T, Reith ME, McDowell S, Cho E, McAleer L, Taylor M, Luedtke RR.

J Med Chem. 2014 Aug 28;57(16):7042-60. doi: 10.1021/jm500801r. Epub 2014 Aug 15.

24.

Multifunctional D2/D3 agonist D-520 with high in vivo efficacy: modulator of toxicity of alpha-synuclein aggregates.

Modi G, Voshavar C, Gogoi S, Shah M, Antonio T, Reith ME, Dutta AK.

ACS Chem Neurosci. 2014 Aug 20;5(8):700-17. doi: 10.1021/cn500084x. Epub 2014 Jul 9.

25.

Dopamine transporter deficiency syndrome: phenotypic spectrum from infancy to adulthood.

Ng J, Zhen J, Meyer E, Erreger K, Li Y, Kakar N, Ahmad J, Thiele H, Kubisch C, Rider NL, Morton DH, Strauss KA, Puffenberger EG, D'Agnano D, Anikster Y, Carducci C, Hyland K, Rotstein M, Leuzzi V, Borck G, Reith ME, Kurian MA.

Brain. 2014 Apr;137(Pt 4):1107-19. doi: 10.1093/brain/awu022. Epub 2014 Mar 10.

26.

Effect of Iboga alkaloids on µ-opioid receptor-coupled G protein activation.

Antonio T, Childers SR, Rothman RB, Dersch CM, King C, Kuehne M, Bornmann WG, Eshleman AJ, Janowsky A, Simon ER, Reith ME, Alper K.

PLoS One. 2013 Oct 16;8(10):e77262. doi: 10.1371/journal.pone.0077262. eCollection 2013.

27.

Aeromonas salmonicida Ati2 is an effector protein of the type three secretion system.

Dallaire-Dufresne S, Barbeau X, Sarty D, Tanaka KH, Denoncourt AM, Lagüe P, Reith ME, Charette SJ.

Microbiology. 2013 Sep;159(Pt 9):1937-45. doi: 10.1099/mic.0.067959-0. Epub 2013 Jul 7.

PMID:
23832001
28.

Nonclassical pharmacology of the dopamine transporter: atypical inhibitors, allosteric modulators, and partial substrates.

Schmitt KC, Rothman RB, Reith ME.

J Pharmacol Exp Ther. 2013 Jul;346(1):2-10. doi: 10.1124/jpet.111.191056. Epub 2013 Apr 8. Review.

29.

Novel structure--function information on biogenic amine transporters revealed by site-directed mutagenesis and alkylation.

Reith ME.

Neurochem Res. 2013 Jul;38(7):1301-2. doi: 10.1007/s11064-013-1025-0. Epub 2013 Mar 27.

31.

Novel bivalent ligands for D2/D3 dopamine receptors: Significant co-operative gain in D2 affinity and potency.

Gogoi S, Biswas S, Modi G, Antonio T, Reith ME, Dutta AK.

ACS Med Chem Lett. 2012 Oct 26;3(12):991-996.

32.

Structural exploration of (3S,6S)-6-benzhydryl-N-benzyltetrahydro-2H-pyran-3-amine analogues: identification of potent triple monoamine reuptake inhibitors as potential antidepressants.

Santra S, Gogoi S, Gopishetty B, Antonio T, Zhen J, Reith ME, Dutta AK.

ChemMedChem. 2012 Dec;7(12):2093-100. doi: 10.1002/cmdc.201200352. Epub 2012 Oct 11.

33.

Importance of cholesterol in dopamine transporter function.

Jones KT, Zhen J, Reith ME.

J Neurochem. 2012 Dec;123(5):700-15. doi: 10.1111/jnc.12007. Epub 2012 Oct 11.

34.

Novel C-1 substituted cocaine analogs unlike cocaine or benztropine.

Reith ME, Ali S, Hashim A, Sheikh IS, Theddu N, Gaddiraju NV, Mehrotra S, Schmitt KC, Murray TF, Sershen H, Unterwald EM, Davis FA.

J Pharmacol Exp Ther. 2012 Nov;343(2):413-25. doi: 10.1124/jpet.112.193771. Epub 2012 Aug 15.

36.

Ibogaine and the inhibition of acetylcholinesterase.

Alper K, Reith ME, Sershen H.

J Ethnopharmacol. 2012 Feb 15;139(3):879-82. doi: 10.1016/j.jep.2011.12.006. Epub 2011 Dec 19.

PMID:
22200647
37.

The atypical stimulant and nootropic modafinil interacts with the dopamine transporter in a different manner than classical cocaine-like inhibitors.

Schmitt KC, Reith ME.

PLoS One. 2011;6(10):e25790. doi: 10.1371/journal.pone.0025790. Epub 2011 Oct 17. Erratum in: PLoS One. 2012;7(1): doi.10.1371/annotation/ba711a7c-13fb-4d18-89a8-28dcc68fcd04..

38.

Characterization of [³H]CFT binding to the norepinephrine transporter suggests that binding of CFT and nisoxetine is not mutually exclusive.

Zhen J, Ali S, Dutta AK, Reith ME.

J Neurosci Methods. 2012 Jan 15;203(1):19-27. doi: 10.1016/j.jneumeth.2011.08.044. Epub 2011 Sep 12.

39.

SKF-83566, a D1-dopamine receptor antagonist, inhibits the dopamine transporter.

Stouffer MA, Ali S, Reith ME, Patel JC, Sarti F, Carr KD, Rice ME.

J Neurochem. 2011 Sep;118(5):714-20. doi: 10.1111/j.1471-4159.2011.07357.x. Epub 2011 Jul 21.

40.

Clinical and molecular characterisation of hereditary dopamine transporter deficiency syndrome: an observational cohort and experimental study.

Kurian MA, Li Y, Zhen J, Meyer E, Hai N, Christen HJ, Hoffmann GF, Jardine P, von Moers A, Mordekar SR, O'Callaghan F, Wassmer E, Wraige E, Dietrich C, Lewis T, Hyland K, Heales S Jr, Sanger T, Gissen P, Assmann BE, Reith ME, Maher ER.

Lancet Neurol. 2011 Jan;10(1):54-62. doi: 10.1016/S1474-4422(10)70269-6. Epub 2010 Nov 25.

41.

The selective dopamine uptake inhibitor, D-84, suppresses cocaine self-administration, but does not occasion cocaine-like levels of generalization.

Batman AM, Dutta AK, Reith ME, Beardsley PM.

Eur J Pharmacol. 2010 Dec 1;648(1-3):127-32. doi: 10.1016/j.ejphar.2010.08.051. Epub 2010 Sep 16.

42.

Interaction of novel hybrid compounds with the D3 dopamine receptor: Site-directed mutagenesis and homology modeling studies.

Kortagere S, Cheng SY, Antonio T, Zhen J, Reith ME, Dutta AK.

Biochem Pharmacol. 2011 Jan 1;81(1):157-63. doi: 10.1016/j.bcp.2010.08.026. Epub 2010 Sep 15.

43.

Substrate and drug binding sites in LeuT.

Nyola A, Karpowich NK, Zhen J, Marden J, Reith ME, Wang DN.

Curr Opin Struct Biol. 2010 Aug;20(4):415-22. doi: 10.1016/j.sbi.2010.05.007. Epub 2010 Jun 16. Review.

44.

Interrelation of dopamine transporter oligomerization and surface presence as studied with mutant transporter proteins and amphetamine.

Li Y, Cheng SY, Chen N, Reith ME.

J Neurochem. 2010 Aug;114(3):873-85. doi: 10.1111/j.1471-4159.2010.06818.x. Epub 2010 May 18.

45.

Aeromonas salmonicida Type I pilus system contributes to host colonization but not invasion.

Dacanay A, Boyd JM, Fast MD, Knickle LC, Reith ME.

Dis Aquat Organ. 2010 Feb 17;88(3):199-206. doi: 10.3354/dao02157.

46.

Regulation of the dopamine transporter: aspects relevant to psychostimulant drugs of abuse.

Schmitt KC, Reith ME.

Ann N Y Acad Sci. 2010 Feb;1187:316-40. doi: 10.1111/j.1749-6632.2009.05148.x. Review.

PMID:
20201860
48.

Concentration of receptor and ligand revisited in a modified receptor binding protocol for high-affinity radioligands: [3H]Spiperone binding to D2 and D3 dopamine receptors.

Zhen J, Antonio T, Dutta AK, Reith ME.

J Neurosci Methods. 2010 Apr 30;188(1):32-8. doi: 10.1016/j.jneumeth.2010.01.031. Epub 2010 Feb 1.

49.

Bivalent phenethylamines as novel dopamine transporter inhibitors: evidence for multiple substrate-binding sites in a single transporter.

Schmitt KC, Mamidyala S, Biswas S, Dutta AK, Reith ME.

J Neurochem. 2010 Mar;112(6):1605-18. doi: 10.1111/j.1471-4159.2010.06583.x. Epub 2010 Jan 12.

Supplemental Content

Loading ...
Support Center